# Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/ > **Published:** 2026-03-26T10:04:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:02-04:00 > **Clinical Summary:** Explore cannabinoid therapies rare diseases with clinical evidence and formulation strategies for less-common disorders in this detailed review. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic Rare DiseasesClinical ReviewFormulation[Evidence-Based Medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/)Individualized Medicine Journal Diseases (Basel, Switzerland) Study Type Clinical Study Population Human participants Why This Matters This review addresses a critical gap in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) by examining evidence for rare and less-studied conditions where traditional therapies may be inadequate. It provides clinicians with a framework for evaluating cannabinoid interventions beyond the well-established indications. Clinical Summary This clinical review synthesizes available evidence for cannabinoid therapies in uncommon medical disorders, examining both clinical outcomes and formulation considerations. The study evaluates various cannabinoid preparations and delivery methods across diverse rare conditions. While the review identifies promising applications, it highlights the limited quality of evidence and small patient populations typical in rare disease research. The authors emphasize the importance of individualized formulation strategies when considering cannabinoids for less-common disorders. Dr. Caplan’s Take “In my practice, rare condition patients often arrive after exhausting conventional options, making [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) a reasonable consideration despite limited evidence. This review reinforces my approach of careful dose titration and close monitoring when venturing into less-studied therapeutic territory.” Clinical Perspective 🧠 Clinicians should view this as a resource for informed decision-making in complex cases rather than definitive treatment guidance. Patients with rare conditions considering [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) warrant detailed informed consent discussions about limited evidence quality and the experimental nature of such interventions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabinoid%20Therapies%20in%20Less-Common%20Disorders%3A%20Clinical%20Evidence%20and%20Formulatio...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41745121/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41745121/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabinoid%20Therapies%20in%20Less-Common%20Disorders%3A%20Clinical%20Evidence%20and%20Formulatio...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41745121/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41745121/](https://pubmed.ncbi.nlm.nih.gov/41745121/) Table of Contents - [FAQ](#FAQ)[What are “less-common disorders” in the context of cannabinoid therapy?](#What_are_8220less-common_disorders8221_in_the_context_of_cannabinoid_therapy) - [How strong is the current clinical evidence for cannabinoids in rare diseases?](#How_strong_is_the_current_clinical_evidence_for_cannabinoids_in_rare_diseases) - [What formulation considerations are important for cannabinoid therapy in rare diseases?](#What_formulation_considerations_are_important_for_cannabinoid_therapy_in_rare_diseases) - [Should clinicians consider cannabinoid therapy for patients with rare diseases?](#Should_clinicians_consider_cannabinoid_therapy_for_patients_with_rare_diseases) - [What does “individualized medicine” mean for cannabinoid therapy in rare diseases?](#What_does_8220individualized_medicine8221_mean_for_cannabinoid_therapy_in_rare_diseases) - [Related](#Related) ## FAQ #### What are “less-common disorders” in the context of cannabinoid therapy? Less-common disorders refer to rare diseases and conditions that affect smaller patient populations and may have limited treatment options. These conditions often lack extensive [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), making cannabinoid therapy an area of emerging interest for patients with unmet medical needs. #### How strong is the current clinical evidence for cannabinoids in rare diseases? The evidence is currently limited and classified as “monitored relevance,” indicating it’s in early-stage development. Most data comes from case reports, small studies, or observational research rather than large randomized controlled trials, requiring careful interpretation and further investigation. #### What formulation considerations are important for cannabinoid therapy in rare diseases? Formulation strategies must account for individual patient variability, bioavailability differences, and precise dosing requirements. Personalized approaches considering factors like age, weight, metabolism, and disease severity are crucial for optimizing therapeutic outcomes in rare conditions. #### Should clinicians consider cannabinoid therapy for patients with rare diseases? Clinicians should approach cannabinoid therapy cautiously, considering it when conventional treatments have failed or are inadequate. Any consideration should involve thorough risk-benefit analysis, patient counseling about limited evidence, and close monitoring for both efficacy and adverse effects. #### What does “individualized medicine” mean for cannabinoid therapy in rare diseases? Individualized medicine involves tailoring cannabinoid treatment to each patient’s specific condition, genetics, and response patterns. This approach is particularly important in rare diseases where standard protocols may not exist, requiring careful dose titration and formulation selection based on individual patient characteristics. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41745121/”, “about”: “diseases basel switzerland clinical study cannabinoid”, “isPartOf”: “Diseases (Basel, Switzerland)”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Lifestyle and Behavioral Enhancements of Sleep: A Review.](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) Explore how lifestyle and behavioral changes can improve sleep quality, complementing cannabinoid therapies in complex cases. [Read More](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) [Pharmacokinetic Study of Natural Hemp Extract-Based Cosmetic Product](https://cedclinic.com/topical-hemp-pharmacokinetics-study-systemic-absorption/) Compare topical and oral administration routes of hemp extracts relevant to formulation strategies in cannabinoid therapies. [Explore Study](https://cedclinic.com/topical-hemp-pharmacokinetics-study-systemic-absorption/) [Sanitation of Medical Cannabis Flowers: Safety and Quality Perspectives](https://cedclinic.com/medical-cannabis-sanitation-technologies-safer-flowers/) Review current and novel sanitation technologies for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) flowers, ensuring safety in cannabinoid formulations. [Learn More](https://cedclinic.com/medical-cannabis-sanitation-technologies-safer-flowers/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).